MabCure has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand. The study aims to evaluate MabCure’s panel of anti-ovarian MAbs in diagnosing
Pfizer and Strides Arcolab have entered into a new collaboration, wherein Pfizer is expected to commercialise off-patent sterile injectable and oral products in the US through its Products
Eisai has completed its acquisition of AkaRx for approximately $255m. As a result of the acquisition, AkaRx is now a wholly-owned subsidiary of Eisai and Eisai has the
Enzon Pharmaceuticals (Enzon) has treated its first patient in the phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38,
MediPEEK-IM advantages are biocompatibility, mechanical strength/toughness, superior hydrolysis and chemical resistance with dimensional stability, sterilizable and radio translucent with natural color. Modern Plastics is a distributor for Westlake
Response Biomedical has received a Notice of Allowance from the European Patent Office for the patent entitled, ‘Sensitive Immunochromatographic Assay’, referred to as the ‘Fong Patent’. The patent
Allon Therapeutics (Allon) has received Japanese patent, covering its two neuroprotection technology platforms. The patent provides protection for the treatment and prevention of a large number of disorders
The US Patent and Trademark Office (USPTO) has issued US Patent No 7638485 titled ‘Modulating Apoptosis’ covering the method of protecting a mammal from radiation using flagellin or
NeoPharm has reported the results of a Phase II clinical trial of Liposome-Entrapped Paclitaxel (LEP) an active component of Taxol. The multicenter, open-label trial of LEP was conducted
Gilead Sciences (Gilead) has reported that Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose ‘Quad’ regimen of elvitegravir, GS 9350 and Truvada (emtricitabine and tenofovir
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.